Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02362672 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of NKTR-181 in Opioid-Naive Subjects With Low Back Pain
A Phase 3 study, sponsored by Nektar Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,189
- Enrollment target
NCT02362672: Completed Phase 3 study, sponsored by Nektar Therapeutics.
NCT02362672 is a Phase 3 study that has completed, run by Nektar Therapeutics. The registered enrollment target is 1,189 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (54% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02362672, a Phase 3 study, has completed, sponsored by Nektar Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,189 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether a new opioid molecule, NKTR-181, is effective for the relief of moderate to severe chronic low back pain as compared to a placebo.
Primary Outcome
The daily pain intensity is an 11-point numerical rating scale ranging from 0 (no pain) to 10 (worst possible pain).
Interventions
- DRUG NKTR-181 BID tablets
- DRUG Placebo to match NKTR-181 BID tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,189 participants |
| Start Date | 2015-03-11 |
| Est. Completion | 2017-02 |
| Phase | Phase 3 |
What the finished NCT02362672 record still lists
NCT02362672 is an interventional study that assigns participants to a tested intervention. Its 1,189 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (54% higher).
The record links to 0 conditions, and to 2 interventions - of which NKTR-181 BID tablets is the first listed.
NCT02362672 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02362672 about?
NCT02362672 is a clinical study titled "Efficacy and Safety Study of NKTR-181 in Opioid-Naive Subjects With Low Back Pain". The purpose of this study is to determine whether a new opioid molecule, NKTR-181, is effective for the relief of moderate to severe chronic low back pain as compared to a placebo.
What is the current status of trial NCT02362672?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,189 participants. The study started on 2015-03-11. Estimated completion is 2017-02.
What interventions are being tested in trial NCT02362672?
The interventions under investigation include: NKTR-181 BID tablets (DRUG), Placebo to match NKTR-181 BID tablets (DRUG).
Who is sponsoring clinical trial NCT02362672?
This trial is sponsored by Nektar Therapeutics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02362672's enrollment target sits among peer trials
1,189 229th of 2000 higher than 1,772 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05580419 · 1,188 participants · NA
Impact of 4PCP on Practitioner and Patient Outcomes
- NCT06290869 · 1,188 participants · Phase 3
Tobacco Education and Lung Health Study (TEAL)
- NCT04293562 · 1,186 participants · Phase 3
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- NCT07177339 · 1,196 participants · Phase 3
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI